Background
Methods
Patients
Treatment
Statistical analysis
Results
Patients’ characteristics
Number (%) | Univariate analysis | ||||
---|---|---|---|---|---|
3Y–PFS (%) |
P value | 3Y–OS (%) |
P value | ||
Gender | |||||
Male | 312(55.3%) | 74.4% | 0.101 | 80.4% | 0.017 |
Female | 252(44.7%) | 78.0% | 92.0% | ||
Age, years | |||||
≤ 60 | 381(67.6%) | 78.6% | 0.062 | 88.3% | 0.002 |
> 60 | 183(32.4%) | 70.2% | 72.1% | ||
Ann Arbor stage | |||||
I,II | 310(55.0%) | 85.6% | <0.001 | 91.8% | <0.001 |
III,IV | 254(45.0%) | 64.4% | 72.8% | ||
LDH(U/L) | |||||
≤ 245 | 337(59.8%) | 84.8% | <0.001 | 91.6% | <0.001 |
> 245 | 227(40.2%) | 62.8% | 70.6% | ||
ECOG PS | |||||
0,1 | 466(82.6%) | 79.9% | <0.001 | 86.3% | <0.001 |
≥ 2 | 98(17.4%) | 57.2% | 68.5% | ||
Extranodal sites | |||||
≤ 1 | 416(73.8%) | 80.3% | <0.001 | 88.2% | 0.017 |
> 1 | 148(26.3%) | 62.5% | 67.2% | ||
IPI | |||||
L | 309(54.8%) | 94.1% | <0.001 | 87.6% | <0.001 |
LI | 96(17.0%) | 84.5% | 72.5% | ||
HI | 96(17.0%) | 64.3% | 57.0% | ||
H | 63(11.2%) | 55.4% | 51.5% | ||
CRP (mg/L) | |||||
≤ 8.6 | 357(63.3%) | 83.7% | <0.001 | 91.2% | <0.001 |
> 8.6 | 207(36.7%) | 64.0% | 70.9% | ||
Albumin levels (g/L) | |||||
< 41.5 | 266(47.2%) | 67.0% | <0.001 | 72.8% | <0.001 |
≥ 41.5 | 298(52.8%) | 83.9% | 92.3% | ||
LMR | |||||
≤ 2.7 | 348(61.7%) | 63.2% | <0.001 | 70.0% | <0.001 |
> 2.7 | 216(38.3%) | 83.9% | 91.4% | ||
NLR | |||||
≤ 4.6 | 436(77.3%) | 82. 3% | <0.001 | 89.0% | <0.001 |
> 4.6 | 128(22.7%) | 60.9% | 68.8% | ||
PLR | |||||
≤ 187.4 | 389(69.0%) | 81.2% | <0.001 | 87.9% | <0.001 |
> 187.4 | 175(31.0%) | 69.1% | 76.6% | ||
Fibrinogen levels (g/L) | |||||
≤ 3.8 | 359(63.6%) | 82.9% | 0.001 | 88.3% | 0.001 |
> 3.8 | 205(36.4%) | 68.8% | 76.2% |
Cut-off values
The novel inflammation-based cumulative prognostic score system (ICPS)
Inflammatory parameters | OS | PFS | ||
---|---|---|---|---|
HR (95% CI) |
P-value | HR (95% Cl) |
P-value | |
Albumin levels(<41.5 g/L) | 2.911(1.533–5.525) | 0.001 | 2.025(1.278–3.208) | 0.003 |
LMR(≤2.7) | 1.966(1.100–3.513) | 0.022 | 1.688(1.062–2.684) | 0.027 |
CRP(>8.6 mg/L) | 1.804(0.983–3.310) | 0.037 | 1.588(0.993–2.541) | 0.054 |
NLR(>4.6) | 0.306 | 0.183 | ||
PLR(>187.4) | 0.604 | 0.205 | ||
Fibrinogen levels (>3.8 g/L) | 0.800 | 0.266 |
Factor | HR | β(HR = eβ) | score |
---|---|---|---|
Albumin levels < 41.5 g/L | 2.245(1.366–3.691) | 0.81 | 1 |
LMR ≤ 2.7 | 2.019(1.225–3.328) | 0.70 | 1 |
CRP > 8.6 mg/L | 1.842(1.102–3.078) | 0.61 | 1 |
Characteristic | OS | PFS | ||
---|---|---|---|---|
P-value | HR (95% Cl) |
P-value | HR (95% Cl) | |
Age(>60y) | <0.001 | 2.493 (1.657–3.749) | 0.250 | 1.228(0.865–1.745) |
Ann Arbor stage(III,IV) | 0.533 | 1.185(0.695–2.022) | 0.295 | 1.254(0.821–1.914) |
LDH(>245 U/L) | 0.042 | 1.690(1.020–2.800) | 0.018 | 1.642(1.087–2.479) |
ECOG PS(≥2) | 0.411 | 1.230(0.751–2.012) | 0.022 | 1.579(1.069–2.330) |
Extranodal sites(>1) | 0.013 | 1.803(1.134–2.868) | 0.187 | 1.305(0.879–1.937) |
ICPS ≥ 2 | 0.001 | 2.476 (1.483–4.136) | 0.019 | 1.611(1.080–2.404) |
Characteristic | OS | PFS | ||
---|---|---|---|---|
P-value | HR (95% Cl) |
P-value | HR (95% Cl) | |
IPI (Hi, H) | <0.001 | 2.697 (1.652–4.405) | 0.001 | 1.892(1.293–1.767) |
ICPS ≥ 2 | <0.001 | 3.044 (1.929–4.804) | <0.001 | 2.293(1.577–3.335) |
Risk group | No.of patients (%) | 3-year OS (%) | RR (95%Cl) |
P-value | 3-year PFS (%) | RR (95%Cl) |
P-value |
---|---|---|---|---|---|---|---|
ICPS = 0 | 202(35.8) | 95.6 | 1.000(N/A) | <0.001 | 86.5 | 1.000(N/A) | <0.001 |
ICPS = 1 | 144(25.5) | 88.2 | 2.270(1.063–4.847) | 0.034 | 82.3 | 1.409(0.838–2.369) | 0.196 |
ICPS = 2 | 99(17.6) | 76.0 | 4.395(2.118–9.118) | <0.001 | 71.6 | 2.241(1.333–3.767) | 0.002 |
ICPS = 3 | 119(21.1) | 62.2 | 8.645(4.482–16.676) | <0.001 | 54.5 | 3.957(2.518–6.216) | <0.001 |